Ausgabe 5/2019
Inhalt (10 Artikel)
Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development
Sherwin K. B. Sy, Luning Zhuang, Serubbabel Sy, Hartmut Derendorf
Cardiovascular Risk Management and Hepatitis C: Combining Drugs
Elise J. Smolders, Peter J. G. ter Horst, Sharon Wolters, David M. Burger
Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation
Camille Tron, Florian Lemaitre, Céline Verstuyft, Antoine Petitcollin, Marie-Clémence Verdier, Eric Bellissant
Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients
Diansong Zhou, Jianguo Li, Khanh Bui, Maria Learoyd, Alienor Berges, Tsveta Milenkova, Nidal Al-Huniti, Helen Tomkinson, Hongmei Xu
Population Pharmacokinetics of Fludarabine in Children and Adults during Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
Jurgen B. Langenhorst, Thomas P. C. Dorlo, Erik M. van Maarseveen, Stefan Nierkens, Jürgen Kuball, Jaap Jan Boelens, Charlotte van Kesteren, Alwin D. R. Huitema
Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus
Hanne Haahr, Thomas R. Pieber, Chantal Mathieu, Theis Gondolf, Masanari Shiramoto, Lars Erichsen, Tim Heise
Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
Sander Bins, Alwin D. R. Huitema, Pim Laven, Samira el Bouazzaoui, Huixin Yu, Nielka van Erp, Carla van Herpen, Paul Hamberg, Hans Gelderblom, Neeltje Steeghs, Stefan Sleijfer, Ron H. N. van Schaik, Ron H. J. Mathijssen, Stijn L. W. Koolen
Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies
Helena Edlund, Sun Ku Lee, Marilee A. Andrew, J. Greg Slatter, Sergey Aksenov, Nidal Al-Huniti
Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials
Yulan Qi, Kathleen McKeever, Julie Taylor, Christine Haller, Wenjie Song, Simon A. Jones, Jack Shi
Correction to: Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials
Yulan Qi, Kathleen McKeever, Julie Taylor, Christine Haller, Wenjie Song, Simon A. Jones, Jack Shi